3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Prostatic Neoplasms
2
Leukemia, Myeloid, Acute
2
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
Sezary Syndrome
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pain, Intractable
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lower Urinary Tract Symptoms
1
Interventions
Fluorouracil
12
Oxaliplatin
11
Leucovorin
10
Irinotecan
7
Capecitabine
7
regorafenib
4
Radiotherapy
4
Bevacizumab
4
aflibercept
2
Reverse Transcriptase Polymerase Chain Reaction
2
Radiation
2
Neoadjuvant Therapy
2
Biopsy
2
tucatinib
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
sulindac sulfone
1
sargramostim
1
pembrolizumab
1
lonafarnib
1
irofulven
1
infigratinib
1
dehydroftorafur
1
balstilimab
1
XELOX
1
Trifluridine
1
Trastuzumab
1
Transplantation
1
Sunitinib
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Rectal Neoplasms
×
Sodium Chloride
×
Clear all
NCT02682485
2023-04-26
SES-DTA
University of Chicago
Phase 2
Withdrawn